December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-005087-10 / Novartis Protocol ID CQVA149A2327

A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation

Trial CQVA149A2327was cancelled with no patient enrollment and as such, no results will be reported.